These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 22337874)

  • 1. MDM2 protein-mediated ubiquitination of numb protein: identification of a second physiological substrate of MDM2 that employs a dual-site docking mechanism.
    Sczaniecka M; Gladstone K; Pettersson S; McLaren L; Huart AS; Wallace M
    J Biol Chem; 2012 Apr; 287(17):14052-68. PubMed ID: 22337874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-site regulation of MDM2 E3-ubiquitin ligase activity.
    Wallace M; Worrall E; Pettersson S; Hupp TR; Ball KL
    Mol Cell; 2006 Jul; 23(2):251-63. PubMed ID: 16857591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Mdm2 acid domain interactions in recognition and ubiquitination of the transcription factor IRF-2.
    Pettersson S; Kelleher M; Pion E; Wallace M; Ball KL
    Biochem J; 2009 Mar; 418(3):575-85. PubMed ID: 19032150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination.
    Ma J; Martin JD; Zhang H; Auger KR; Ho TF; Kirkpatrick RB; Grooms MH; Johanson KO; Tummino PJ; Copeland RA; Lai Z
    Biochemistry; 2006 Aug; 45(30):9238-45. PubMed ID: 16866370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant p53 Sequestration of the MDM2 Acidic Domain Inhibits E3 Ligase Activity.
    Yang L; Song T; Cheng Q; Chen L; Chen J
    Mol Cell Biol; 2019 Feb; 39(4):. PubMed ID: 30455251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical contribution of the MDM2 acidic domain to p53 ubiquitination.
    Kawai H; Wiederschain D; Yuan ZM
    Mol Cell Biol; 2003 Jul; 23(14):4939-47. PubMed ID: 12832479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exon 3 of the
    Confalonieri S; Colaluca IN; Basile A; Pece S; Di Fiore PP
    G3 (Bethesda); 2019 Oct; 9(10):3359-3367. PubMed ID: 31451549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoactivation of the MDM2 E3 ligase by intramolecular interaction.
    Cheng Q; Song T; Chen L; Chen J
    Mol Cell Biol; 2014 Aug; 34(15):2800-10. PubMed ID: 24842904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A site-directed mutagenesis study of the MdmX RING domain.
    Egorova O; Mis M; Sheng Y
    Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-degradative ubiquitination of the Notch1 receptor by the E3 ligase MDM2 activates the Notch signalling pathway.
    Pettersson S; Sczaniecka M; McLaren L; Russell F; Gladstone K; Hupp T; Wallace M
    Biochem J; 2013 Mar; 450(3):523-36. PubMed ID: 23252402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting RING domains of Mdm2-MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells.
    Wu W; Xu C; Ling X; Fan C; Buckley BP; Chernov MV; Ellis L; Li F; Muñoz IG; Wang X
    Cell Death Dis; 2015 Dec; 6(12):e2035. PubMed ID: 26720344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo.
    Shimizu H; Burch LR; Smith AJ; Dornan D; Wallace M; Ball KL; Hupp TR
    J Biol Chem; 2002 Aug; 277(32):28446-58. PubMed ID: 11925449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of phosphomimetic lid mutation on the thermostability of the N-terminal domain of MDM2.
    Worrall EG; Worrall L; Blackburn E; Walkinshaw M; Hupp TR
    J Mol Biol; 2010 May; 398(3):414-28. PubMed ID: 20303977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphomimetic mutation of the N-terminal lid of MDM2 enhances the polyubiquitination of p53 through stimulation of E2-ubiquitin thioester hydrolysis.
    Fraser JA; Worrall EG; Lin Y; Landre V; Pettersson S; Blackburn E; Walkinshaw M; Muller P; Vojtesek B; Ball K; Hupp TR
    J Mol Biol; 2015 Apr; 427(8):1728-47. PubMed ID: 25543083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bivalent binding of p14ARF to MDM2 RING and acidic domains inhibits E3 ligase function.
    Kowalczyk D; Nakasone MA; Smith BO; Huang DT
    Life Sci Alliance; 2022 Aug; 5(12):. PubMed ID: 35944929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGCG binds intrinsically disordered N-terminal domain of p53 and disrupts p53-MDM2 interaction.
    Zhao J; Blayney A; Liu X; Gandy L; Jin W; Yan L; Ha JH; Canning AJ; Connelly M; Yang C; Liu X; Xiao Y; Cosgrove MS; Solmaz SR; Zhang Y; Ban D; Chen J; Loh SN; Wang C
    Nat Commun; 2021 Feb; 12(1):986. PubMed ID: 33579943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Auto-ubiquitination of Mdm2 enhances its substrate ubiquitin ligase activity.
    Ranaweera RS; Yang X
    J Biol Chem; 2013 Jun; 288(26):18939-46. PubMed ID: 23671280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-terminal region of USP7/HAUSP is critical for deubiquitination activity and contains a second mdm2/p53 binding site.
    Ma J; Martin JD; Xue Y; Lor LA; Kennedy-Wilson KM; Sinnamon RH; Ho TF; Zhang G; Schwartz B; Tummino PJ; Lai Z
    Arch Biochem Biophys; 2010 Nov; 503(2):207-12. PubMed ID: 20816748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function.
    Nihira NT; Ogura K; Shimizu K; North BJ; Zhang J; Gao D; Inuzuka H; Wei W
    Sci Signal; 2017 Feb; 10(466):. PubMed ID: 28196907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NUMB controls p53 tumour suppressor activity.
    Colaluca IN; Tosoni D; Nuciforo P; Senic-Matuglia F; Galimberti V; Viale G; Pece S; Di Fiore PP
    Nature; 2008 Jan; 451(7174):76-80. PubMed ID: 18172499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.